Skip to main content

HER2 Biological Pathways Reviews

Videos

Ciara O'Sullivan, MD
Videos
02/04/2025
Ciara O’Sullivan, MD, outlines the objectives of the CompassHER2 RD trial which aims to evaluate T-DM1 plus tucatinib in a cohort of patients with high-risk, HER2-positive early breast cancer.
Ciara O’Sullivan, MD, outlines the objectives of the CompassHER2 RD trial which aims to evaluate T-DM1 plus tucatinib in a cohort of patients with high-risk, HER2-positive early breast cancer.
Ciara O’Sullivan, MD, outlines...
02/04/2025
Oncology
Junjie Li, MD
Conference Coverage
12/12/2024
Results from a phase 2 study found that SHR-A1822, a novel third generation HER2-directed antibody-drug conjugate, showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.
Results from a phase 2 study found that SHR-A1822, a novel third generation HER2-directed antibody-drug conjugate, showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.
Results from a phase 2 study...
12/12/2024
Oncology
Giuseppe Viale, MD
Conference Coverage
10/29/2024
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses...
10/29/2024
Oncology
Oleg Gluz, MD
Videos
09/15/2024
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results...
09/15/2024
Oncology
Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
06/20/2024
Erika Hamilton, MD
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the...
06/20/2024
Oncology
Sara Hurvitz, MD, Fred Hutchinson Cancer Center
Videos
12/06/2023
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results...
12/06/2023
Oncology
Clinton Yam, MD, MD Anderson Cancer Center, Houston, TX
Videos
03/06/2023
At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.
At the 2022 San Antonio Breast...
03/06/2023
Oncology
Aditya Bardia, MD, Massachusetts General Hospital, Boston, MA
Videos
02/02/2023
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.
At the 2022 San Antonio Breast...
02/02/2023
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine
Videos
12/22/2022
At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.
At the 2022 San Antonio Breast...
12/22/2022
Oncology
Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
09/12/2022
Erika Hamilton, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-low metastatic breast cancer and the data that led to this approval.
Erika Hamilton, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-low metastatic breast cancer and the data that led to this approval.
Erika Hamilton, MD, shares...
09/12/2022
Oncology
Videos
02/13/2025
Mohamed S. Abdelbaki, MD, discusses the course of treatment he would take for a patient with BRAF V600E-mutated pediatric low-grade glioma.
Mohamed S. Abdelbaki, MD, discusses the course of treatment he would take for a patient with BRAF V600E-mutated pediatric low-grade glioma.
Mohamed S. Abdelbaki, MD,...
02/13/2025
Oncology
Mateo Mejia Saldarriaga, MD
Videos
02/12/2025
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD...
02/12/2025
Oncology
Melissa Alsina, MD
Conference Coverage
02/12/2025
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses...
02/12/2025
Oncology
Anna-Dorothea Wagner, MD
Conference Coverage
02/11/2025
Anna-Dorothea Wagner, MD, discusses results from the INNOVATION trial which found the addition of trastuzumab to FLOT chemotherapy did not improve survival outcomes for patients with HER2-positive gastric cancers.
Anna-Dorothea Wagner, MD, discusses results from the INNOVATION trial which found the addition of trastuzumab to FLOT chemotherapy did not improve survival outcomes for patients with HER2-positive gastric cancers.
Anna-Dorothea Wagner, MD,...
02/11/2025
Oncology
Marwan Fakih, MD
Conference Coverage
02/11/2025
Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.
Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.
Marwan Fakih, MD, discusses...
02/11/2025
Oncology
Matthew Davids, MD, MMSc
Videos
02/09/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia &...
02/09/2025
Oncology
KOL Roundtable
Videos
02/08/2025
In part 4 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss innovative myelofibrosis treatments and exciting new data on future therapies with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 4 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss innovative myelofibrosis treatments and exciting new data on future therapies with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 4 of this expert...
02/08/2025
Oncology
Videos
02/08/2025
In part 3 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss therapies for patients with relapsed or refractory myelofibrosis with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 3 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss therapies for patients with relapsed or refractory myelofibrosis with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 3 of this expert...
02/08/2025
Oncology
Sangeetha Venugopal, MD
Videos
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
Gabriela Hobbs, MD
Videos
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Gabriela Hobbs, MD, discusses innovative therapies and strategies for treating patients with myeloproliferative neoplasms.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Gabriela Hobbs, MD, discusses innovative therapies and strategies for treating patients with myeloproliferative neoplasms.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
OLN

HER2

ALIASES

ERBB2; CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1; erb-b2 receptor tyrosine kinase 2

Human epidermal growth factor receptor 2 (HER2) is 1 of 4 transmembrane tyrosine kinase receptor proteins in the epidermal growth factor receptor family.1,2 Normally expressed on epithelial cellular membranes of organs such as breast and skin, HER2 exists in other tissues, including gastrointestinal, respiratory, reproductive, urinary tract tissues, and more.2,3

HER2-positive status is both a prognostic indicator of poor outcomes and predictive biomarker of treatment response to HER2-targeted therapies.2,4 The effectiveness of emerging therapies, such as HER2-specific antibodies and antibody-drug conjugates, somewhat depends on the ability of agents to bind to cell surface targets then efficiently internalize and accumulate the cytotoxic agent while preserving host tissues.4

Understanding the Role of HER2

This animation explains the role of HER2 in the regulation of cell growth and the negative effects of HER2 overexpression.

Expression in Cancer

HER2-positivity is found in a variety of cancer types. The graphic below displays the expression of HER2-positivity in up to a certain percentage of cases in each cancer type.

Breast Cancer
20%
Lung Cancer
1.1%
Ovarian Cancer
1.6%
Gastric Cancer
4.7%
Esophageal Cancer
11.3%
Uterine Cancer
3%
Cervical Cancer
2.2%
Endometrial Cancer
3.4%
Gallbladder Cancer
9.8%
Cholangiocarcinoma
6.3%
Bladder Cancer
3.6%
Colorectal Cancer
1.3%
Salivary Cancer
37%
Vaginal Cancer
3.6%
Testicular Cancer
2.4%
Head and Neck Cancer
1.3%
Pancreatic Cancer
0.7%
Prostate Cancer
0.6%

Resources

News
02/07/2025
Updated results from the phase 3 KATHERINE trial demonstrated that trastuzumab emtansine improved survival among previously treated patients with HER2-positive early breast cancer.
Updated results from the phase 3 KATHERINE trial demonstrated that trastuzumab emtansine improved survival among previously treated patients with HER2-positive early breast cancer.
Updated results from the phase 3...
02/07/2025
Oncology
News
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
Conference Coverage
12/03/2024
According to a phase 2 study, the novel HER2-directed antibody-drug conjugate SHR-A1811 showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.
According to a phase 2 study, the novel HER2-directed antibody-drug conjugate SHR-A1811 showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.
According to a phase 2 study,...
12/03/2024
Oncology
FDA Alerts
11/21/2024
Based on results from cohort 1 of the phase 2b HERIZON-BTC-01 trial, the US FDA has approved zanidatamab for patients with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who experience disease progression on or...
Based on results from cohort 1 of the phase 2b HERIZON-BTC-01 trial, the US FDA has approved zanidatamab for patients with unresectable locally advanced or metastatic HER2-positive biliary tract cancer who experience disease progression on or...
Based on results from cohort 1...
11/21/2024
Oncology
News
09/05/2024
According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.
According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.
According to results from the...
09/05/2024
Oncology
News
08/14/2024
According to results from a phase 2 study, trastuzumab deruxtecan demonstrated promising activity among patients with HER2-expressing unresectable or recurrent biliary tract cancer.
According to results from a phase 2 study, trastuzumab deruxtecan demonstrated promising activity among patients with HER2-expressing unresectable or recurrent biliary tract cancer.
According to results from a...
08/14/2024
Oncology
News
07/25/2024
According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.
According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.
According to results from a...
07/25/2024
Oncology
News
12/08/2023
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a...
12/08/2023
Oncology
News
12/08/2023
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
News
08/10/2023
According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...
According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...
According to a systemic review...
08/10/2023
Oncology
Conference Coverage
02/13/2025
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion...
02/13/2025
Oncology
Conference Coverage
02/13/2025
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...
According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...
According to results from the...
02/13/2025
Oncology
Conference Coverage
02/13/2025
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of...
02/13/2025
Oncology
News
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
FDA Approval
02/12/2025
On February 11, 2025, the US Food and Drug Administration approved brentuximab vedotin with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-Cell lymphoma.
On February 11, 2025, the US Food and Drug Administration approved brentuximab vedotin with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-Cell lymphoma.
On February 11, 2025, the US...
02/12/2025
Oncology
FDA Approval
02/11/2025
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase...
02/11/2025
Oncology
News
02/11/2025
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology
News
02/11/2025
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of...
02/11/2025
Oncology

Podcasts

Podcasts
12/11/2019
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan...
12/11/2019
Oncology
Podcasts
12/10/2019
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Memorial Sloan...
12/10/2019
Oncology
Podcasts
11/29/2019
Sherene Loi, MD, PhD, talks about how the treatment of early stage, HER2-positive breast cancer has evolved.
Sherene Loi, MD, PhD, talks about how the treatment of early stage, HER2-positive breast cancer has evolved.
Sherene Loi, MD, PhD, talks...
11/29/2019
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Interactive

Quiz
02/07/2025
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine...
02/07/2025
Oncology
Quiz
10/03/2024
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811...
10/03/2024
Oncology
Test Your Knowledge
02/04/2022
True or false: Trastuzumab deruxtecan showed superiority over chemo in HER2+ gastric cancer.
True or false: Trastuzumab deruxtecan showed superiority over chemo in HER2+ gastric cancer.
True or false: Trastuzumab...
02/04/2022
Oncology
Test Your Knowledge
01/31/2022
True or false: Currently, there are many HER2 targeted therapies approved for NSCLC.
True or false: Currently, there are many HER2 targeted therapies approved for NSCLC.
True or false: Currently, there...
01/31/2022
Oncology
Quiz
08/20/2021
True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.
True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.
True or false: In a recent phase...
08/20/2021
Oncology
Quiz
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology
Quiz
02/07/2025
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine...
02/07/2025
Oncology
Quiz
01/22/2025
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of...
01/22/2025
Oncology
Quiz
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology